Combretastatin Analogs with Tubulin Binding Activity
申请人:PINNEY Kevin G.
公开号:US20090075943A1
公开(公告)日:2009-03-19
Analogs of combretastatin have been discovered which demonstrate impressive cytotoxicity as well as a remarkable ability to inhibit tubulin polymerization. Such compounds are excellent clinical candidates for the treatment of cancer in humans. In addition, certain of these ligands, as pro-drugs, may well prove to be tumor selective vascular targeting chemotherapeutic agents or to have vascular targeting activity resulting in the selective prevention and/or destruction of nonmalignant proliferating vasculature.
COMBRETASTATIN ANALOGS WITH TUBULIN BINDING ACTIVITY
申请人:BAYLOR UNIVERSITY
公开号:EP1896391B1
公开(公告)日:2015-08-12
US7429681B2
申请人:——
公开号:US7429681B2
公开(公告)日:2008-09-30
US8394859B2
申请人:——
公开号:US8394859B2
公开(公告)日:2013-03-12
[EN] COMBRETASTATIN ANALOGS WITH TUBULIN BINDING ACTIVITY<br/>[FR] ANALOGUES COMBRESTATINIQUES A ACTIVITE DE LIAISON AVEC LA TUBULINE
申请人:UNIV BAYLOR
公开号:WO2006138427A2
公开(公告)日:2006-12-28
[EN] Analogs of combretastatin have been discovered which demonstrate impressive cytotoxicity as well as a remarkable ability to inhibit tubulin polymerization. Such compounds are excellent clinical candidates for the treatment of cancer in humans. In addition, certain of these ligands, as pro-drugs, may well prove to be tumor selective vascular targeting chemotherapeutic agents or to have vascular targeting activity resulting in the selective prevention and/or destruction of nonmalignant proliferating vasculature. [FR] La présente invention concerne des analogues combrestatiniques faisant preuve d'une importante cytotoxicité ainsi que d'une remarquable aptitude à inhiber la polymérisation tubulinique. De tels composés sont d'excellents candidats cliniques pour le traitement de cancers humains. En outre, certains de ces ligands, en tant que pro-médicaments, sont vraisemblablement des chimiothérapiques tumeur-sélectifs à ciblage vasculaire ou présentant d'une activité de ciblage vasculaire permettant d'envisager une prévention sélective et/ou une destruction de vascularisations bénignes proliférantes.